Empery alleges critical clinical trial misrepresentations by seelos therapeutics

New york--(business wire)--empery asset management, lp (“empery”) wishes to inform shareholders of seelos therapeutics, inc (the “company” or “seelos”) that empery transmitted a letter to management and the board of directors of seelos alleging material misrepresentations that the company's ceo made regarding the sls-002 phase ii study in adults with major depressive disorder at imminent risk of suicide (the “trial”). the company made public disclosures about the intended size of the trial to b.
SEEL Ratings Summary
SEEL Quant Ranking